Mirum Says Atebrioz Reduced Bone Lesion Volume in FOP Trial
Mirum reported reduced bone lesion volume in a trial of Atebrioz in children aged 6 to under 12.
Mirum reported reduced bone lesion volume in a trial of Atebrioz in children aged 6 to under 12.